KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) EBT (2016 - 2025)

Neogenomics' EBT history spans 16 years, with the latest figure at -$12.4 million for Q4 2025.

  • For Q4 2025, EBT rose 23.08% year-over-year to -$12.4 million; the TTM value through Dec 2025 reached -$110.3 million, down 36.68%, while the annual FY2025 figure was -$110.3 million, 36.68% down from the prior year.
  • EBT reached -$12.4 million in Q4 2025 per NEO's latest filing, up from -$26.4 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $73.4 million in Q2 2021 to a low of -$53.2 million in Q1 2022.
  • Average EBT over 5 years is -$23.1 million, with a median of -$25.6 million recorded in 2022.
  • The largest YoY upside for EBT was 508.98% in 2021 against a maximum downside of 1142.75% in 2021.
  • A 5-year view of EBT shows it stood at -$44.2 million in 2021, then soared by 42.26% to -$25.5 million in 2022, then surged by 40.11% to -$15.3 million in 2023, then decreased by 5.51% to -$16.1 million in 2024, then increased by 23.08% to -$12.4 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's EBT are -$12.4 million (Q4 2025), -$26.4 million (Q3 2025), and -$45.8 million (Q2 2025).